Ceftaroline

Background

Mechanism of Action

• Binds to and inhibits PBP-2a

Spectrum of Activity

• Active against MRSA, Staphylococcus epidermidis, aerobic Gram-negative bacilli (similar to ceftriaxone)
• Low to moderate activity against Enterococcus
• Not active against Pseudomonas, ESBL-producers, or AmpC-producers

Pharmacokinetics and Pharmacodynamics

• Crosses in CSF adequately

Dosing

• SSTI: ceftaroline 600 mg IV q12h
• Pneumonia and bacteremia: ceftaroline 600 mg IV q8h

Safety

Adverse Drug Reactions

• Rash, eosinophilia, reversible neutropenia (20% when ≥3 weeks)